²ÝݮӰÊÓ

Dr. Mike Pellini is a managing partner of Section 32, a venture capital fund investing at the frontiers of technology, health care, and life sciences. Prior to joining Section 32 in 2017, he served as CEO and then chairman of Foundation Medicine, a company that transformed the way pharmaceutical companies and physicians evaluate the genomic changes underlying a patient¡¯s cancer, through the close of Roche¡¯s acquisition in August 2018. Previously, Dr. Pellini was president and COO of Clarient, a national leader in molecular pathology, which was acquired by GE Healthcare in 2010. Dr. Pellini brings a breadth of understanding in personalized medicine, with a lifetime interest and focus on defeating cancer. He currently serves as a member of the boards for TwinStrand Genomics, Nusano, Singular Genomics (¡®OMIC¡¯), Adaptive Biotechnologies (¡®ADPT¡¯), Octave BioSciences, and Exai Bio. He previously served on the boards of Thrive Earlier Detection, which was acquired by Exact Sciences (¡®EXACT¡¯) in January 2021, Tango Therapeutics (¡®TNGX¡¯), the Personalized Medicine Coalition, and the Mission Hospital Foundation. He was also a member of the President¡¯s Leadership Council at Thomas Jefferson University.? Dr. Pellini joined the American Cancer Society Board of Directors in 2023.